🇺🇸 Pioglitazone + Alogliptin in United States
5 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 5
Most-reported reactions
- Acute Kidney Injury — 1 report (20%)
- Altered State Of Consciousness — 1 report (20%)
- Drug Level Increased — 1 report (20%)
- Dyspnoea — 1 report (20%)
- Lactic Acidosis — 1 report (20%)
Other Diabetes approved in United States
Frequently asked questions
Is Pioglitazone + Alogliptin approved in United States?
Pioglitazone + Alogliptin does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Pioglitazone + Alogliptin in United States?
Celltrion Pharm, Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.